NervGen Pharma (NASDAQ:NGEN) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of NervGen Pharma (NASDAQ:NGEN) from a sell rating to a hold rating in a research report sent to investors on Monday.

A number of other research analysts also recently issued reports on the stock. Leerink Partners began coverage on shares of NervGen Pharma in a research note on Monday, July 13th. They issued an “outperform” rating and a $10.00 price target for the company. Stifel Nicolaus raised shares of NervGen Pharma to a “strong-buy” rating in a research report on Thursday, April 23rd. Weiss Ratings assumed coverage on shares of NervGen Pharma in a research report on Friday, April 24th. They issued a “sell (d-)” rating on the stock. HC Wainwright upgraded shares of NervGen Pharma to a “strong-buy” rating in a report on Tuesday, April 28th. Finally, Zacks Research raised shares of NervGen Pharma to a “hold” rating in a research report on Wednesday, April 29th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

NervGen Pharma Stock Up 3.6%

NGEN stock opened at $1.73 on Monday. The firm has a market cap of $139.49 million and a price-to-earnings ratio of -19.22. The firm has a 50-day moving average of $2.23. NervGen Pharma has a 1 year low of $1.59 and a 1 year high of $6.30.

NervGen Pharma (NASDAQ:NGEN) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02).

About NervGen Pharma

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.